Back to mobile site

Rigel Pharmaceuticals, Inc. (RIGL) Reports In-Line Q2 EPS

August 7, 2012 7:33 AM EDT
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q2 EPS of ($0.35), in-line with the analyst estimate of ($0.35). Revenue for the quarter came in at $1.15 million versus the consensus estimate of $550 thousand.

For earnings history and earnings-related data on Rigel Pharmaceuticals, Inc. (RIGL) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings